NCT03746223 is a Phase 2 clinical trial of Methotrexate in Primary Intraocular Lymphoma, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT03746223?

NCT03746223 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT03746223?

Interventions in NCT03746223: Methotrexate, Rituximab, Lenalidomide.

What condition does NCT03746223 study?

NCT03746223 studies Primary Intraocular Lymphoma.

Is NCT03746223 still recruiting?

NCT03746223 is currently status unknown. Last updated 9 October 2019.

Last reviewed 2019-10-09 · How we verify

NCT03746223

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma

Status unknown Phase 2 Last updated 9 October 2019

What this trial tests

Phase 2 trial testing Methotrexate in Primary Intraocular Lymphoma in 42 participants. Status unknown.

Timeline

15 November 2018

Primary endpoint
15 November 2020

15 October 2025

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	15 November 2018
Primary completion	15 November 2020
Estimated completion	15 October 2025
Sites	1 location across China

Drugs / interventions tested

Methotrexate — full drug profile →
Rituximab — full drug profile →
Lenalidomide — full drug profile →

Conditions studied

Primary Intraocular Lymphoma — all drugs for Primary Intraocular Lymphoma →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 75, any sex, with Primary Intraocular Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective single arm phase II study, and the purpose of this study is to evaluate the efficiency of R2 regimen (rituximab \& lenalidomide) combined with intravitreal methotrexate and followed by lenalidomide maintenance in newly-diagnosed primary intraocular lymphoma. Progression free survival (PFS) of the cohort is the primary endpoint.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study.
Zhang Y, Zhang X, Zou D, Yin J, et al · · 2021 · cited 13× · PMID 34249763 · DOI 10.3389/fonc.2021.701507
Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis.
Zhuang Z, Zhang Y, Zhang X, Zhang M, et al · · 2022 · cited 7× · PMID 36059608 · DOI 10.3389/fonc.2022.955080
Relapses and outcomes of systemic chemo-free therapies combined with intravitreous methotrexate in isolated primary vitreoretinal lymphoma: an analysis based on two prospective cohort studies.
Chen H, Zhuang Z, Zhang X, Zhou D, et al · · 2025 · PMID 40415007 · DOI 10.1007/s00277-025-06414-x

Verify or expand the search:

Other trials of Methotrexate

Trials testing the same drug.

NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07321912 — Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma · Phase 2 · not yet recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07477691 — Immune Modulation During Palynziq® Treatment in Adults (IMPALA) · Phase 4 · not yet recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03746223 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 9 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03746223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing